USP9X

Across TCGA pan-cancer cohorts, USP9X mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated USP9X data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher USP9X mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated USP9X expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where USP9X mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.678	0.898	<.001	71	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.274	.001	54	view →
CCRCC	OS	Tertile	All	0.591	0.892	.017	4	view →
HNSC	OS	Quartile	IV	1.000	0.741	.004	4	view →
LSCC	OS	Tertile	All	1.000	0.938	.042	1	view →
GBM	OS	Tertile	All	0.464	0.613	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

USP9X–PDAC (DFS)

Open the PDAC breakdown →